Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial. Real ...

The second most common cancer in the hematologic (blood) cancer category is multiple myeloma. It accounts for about 13% of all cases of blood cancer. 63% of ...

European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.

In this video, Hamza Hassan, MD, assistant professor of oncology at Roswell Park Comprehensive Cancer Center, discusses the baseline characteristics of the case. Editor's note: The following is an ...

In this video, Ehsan Malek, MD, director of the multiple myeloma translational research program and associate professor of oncology at Roswell Park Comprehensive Cancer Center, discusses the baseline ...

Initial uptake of bispecific antibodies for multiple myeloma is promising, especially for Black patients, aligning with disease prevalence. Further data on social determinants and insurance status are ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or ...

Anemia often goes hand-in-hand with multiple myeloma. Sometimes, the cancer causes the anemia. And sometimes, the cancer treatment does. But it's possible to resolve it and feel better. (Photo Credit: ...